South Africa is rolling out lenacapavir, a twice-yearly injectable drug used for HIV prevention, as President Cyril Ramaphosa officially launches the national programme. The Presidency says the medication will expand biomedical tools in the country’s response to HIV and is intended to reduce new infections through long-term public health interventions.
Reporting across outlets describes lenacapavir as a long-acting option for people at risk of HIV, with provinces beginning phased implementation. The Western Cape Department of Health and Wellness starts rollout activities at 22 facilities. Gauteng is preparing a broader phase of distribution through 133 clinics, targeting about 56,000 people deemed at high risk.
International coverage highlights the scale of the initiative given South Africa’s high HIV burden, describing the arrival of lenacapavir as a significant step in HIV prevention efforts. While the outlets emphasize the programme’s expected impact and the government’s framing, the core details across sources remain consistent: lenacapavir is administered twice a year and is being introduced through provincial rollout sites following the national launch.
